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Paul WicksAbstract
The system of medical discovery does not revolve around patients as unique individuals with preferences, needs,
and desires. Rather it revolves around scientific scrutiny, the needs of the sponsor, and the desires for regulatory
approval. The patient is only a subject. Is it any wonder, then, that some patients have rejected the current medical
paradigm and sought to find their own path?
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For an individual used to the uncanny intelligence that
drives the personalized content you see on Amazon or
Google, the experience of being a clinical trial partici-
pant must seem like a blast from the 1980s. Rather than
receiving a welcoming email that alerts you to upcoming
trials, you might get a letter in the post that has so much
medical jargon it can only be understood by a scientific
expert. Or you might have a hasty conversation with
your doctor who knows few of the details and has even
less time to explain them.
The system of medical discovery does not revolve
around patients as unique individuals with preferences,
needs, and desires. Rather it revolves around scientific
scrutiny, the needs of the sponsor, and their desire for
regulatory approval. The patient is only a subject. Is it any
wonder, then, that some patients have rejected the current
medical paradigm and sought to find their own path?
Participant led research
In the rare and terminal condition amyotrophic lateral
sclerosis (ALS) there has been evidence from as far back
as 2004 [1] of patients violating protocol by taking experi-
mental creatine supplements off-label when they were
meant to be on the placebo arm. More recently, when a
small phase II study reported that lithium carbonate might
halt the progression of the disease in a small sample of
16 patients treated with lithium and riluzole relative to
28 patients on riluzole alone, patients rapidly mobilizedCorrespondence: pwicks@patientslikeme.com
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Within just six months a group of 160 patients had con-
vened online and were tracking their disease progression,
lithium blood levels, and side effects to discover whether
they could crowdsource a study faster than the trad-
itional medical establishment [2]. In the end, an analysis
performed by PatientsLikeMe showed that lithium had
no effect [3], a finding confirmed by a number of clinical
trials in later years [4]. Some patients even went on to
perform similar attempts at crowdsourcing while par-
ticipating in randomized controlled trials, pooling their
side effects to try and unblind themselves [5]. Scientifically
these protocol violations are a concern, but from an advo-
cate’s perspective they seem like a reasonable reaction.
Might there be a middle ground?Patient centered trial design
A promising example from the iSPY-2 breast cancer trial
suggests that integrating patients as informed decision
makers rather than strictly as subjects may optimize study
design, create better recruitment materials, minimize attri-
tion, and ensure meaningful dissemination of trial results
to women affected by the disease. Although it took more
time and resources, the study investigators recruited up
to 50 patients to advise, co-design, translate recruitment
materials into other languages, and even sit on scientific
advisory committees within the trial infrastructure [6].
As a result blind spots were illuminated by patients before
recruitment started and researchers managed to suc-
cessfully enroll participants in a study with a fairly inva-
sive protocol of repeated biopsies and imaging.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Rheumatology (OMERACT) group, which invited rheuma-
toid arthritis (RA) patient advocates to participate in their
bi-annual meetings to identify important outcome mea-
sures. Outcomes that matter to patients that had previously
flown under the radar, such as fatigue, flare-ups, sleep
disturbance, and foot pain were identified. Further-
more, advocates reported a cultural change that arises
from having patients in the room when decisions are
being made [7].
Discussion
As enticing as these examples sound, it is worth noting
that they are the exception rather than the rule. This is
in part due to the cultural and logistical issues involved
[6,8]. One potential advantage of newer digital technology
is that it might be possible to scale patient involvement in
a way that is not overly burdensome for either patient or
researcher, and that can entice ongoing involvement
throughout the trial. For example, we have found that
by iterating on digital feedback mechanisms, we can
bring the time needed for certain aspects of psychometric
validation for patient-reported outcome measures down
from months to days [9], with online patients eager to
offer feedback if tools are convenient and engaging.
Some early efforts are underway at the earliest end of
the funnel, awareness. Charities and non-profits such as
the Michael J Fox Foundation have built tools like the
Fox Trial Finder (https://foxtrialfinder.michaeljfox.org/),
which explains the importance of trials, and hosts lay
summaries of many clinical trials, albeit mostly in the
United States. Online startup companies such as Trial-
Reach.com attempt to match patients to trials and provide
services to help provide lay summaries and reach out to
patients where they are. PatientsLikeMe pulls in all the
data from ClinicalTrials.gov each night and matches it to
over 250,000 globally registered patients in their system
so that those who want to can find local trials that match
their clinical profile. The trial registries themselves are
making strides to improve the ability of patients and
researchers to come together, and the ISRCTN Register
(hosted by Biomed Central) are exploring new ways to
support researchers in providing lay summaries and
research feedback.
Conclusion
By harnessing online patient communities it is possible
to recruit a representative population of dozens or even
hundreds of patients to provide qualitative and quantitative
feedback at each phase of the trial recruitment process. Dir-
ect patient input and involvement about the relative im-
portance of research questions, the unmet need in their
disease, potential barriers to recruitment in trial protocols
recruitment materials, and, once completed, even thewriting of the lay summary of trial results can improve
public understanding of science. Such tools might only
be applicable to certain diseases with high enough levels
of online engagement, but the status quo is that for
very few conditions do trials have any sort of patient in-
volvement or co-design. Given the well-documented
struggles many trials have to meet their targets, it at
least warrants experimentation. The advantage in doing
so with software versus traditional models is a more
rapid iteration in response to feedback and learning,
though there are likely to be downsides to over-reliance on
purely digital methods, such as biases, which will need to
be addressed [10].
If patients are increasingly comfortable sharing their
data and providing feedback as consumers in areas as
diverse as shopping, hotels, and restaurants, what have we
got to lose in trying to engage them as peers in designing
better research?
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